Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine.
about
Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overviewCancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapiesApplications of PET imaging with the proliferation marker [18F]-FLTImaging biomarkers in primary brain tumours.Imaging and 'omic' methods for the molecular diagnosis of cancer.Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer.Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research.Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.Widefield optical imaging of changes in uptake of glucose and tissue extracellular pH in head and neck cancer.Functional imaging for prostate cancer: therapeutic implications.High-resolution optical molecular imaging of changes in choline metabolism in oral neoplasia.Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcomeIncreased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft modelInterrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging.Recent Advances in Metabolic Profiling And Imaging of Prostate Cancer.Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer.
P2860
Q26767172-0997018E-6FAC-42D2-A275-90B3EF59B3DDQ26823118-C801E27B-AF2C-4D20-A9C0-E4C0880034E1Q28083952-CC26C048-DBBF-4376-8A16-E14F530D7685Q30880129-ED776416-2B57-42DD-99A2-A46EBC9F8B0AQ33577268-A0248C98-A83B-4CEC-BB71-B9F3A75C48FDQ33750115-91898495-87DD-4D40-8086-571C4FA507ADQ34551523-E9099DC2-6CFD-4846-97A4-2E727138E75CQ34826426-9F31C9FC-59C6-4934-A6B5-77AF9A27E7DEQ35067622-EE660075-ABC8-4C9B-BCC7-364C154ACF2DQ35349316-6C1934BB-1C6C-41FC-B5DA-7A7ED3024C58Q36128629-2FFD2666-1BD7-4292-B24E-43DFA35EA442Q36613308-9AF7E3FC-549F-49C2-A0C0-613355F921A9Q37170012-363130CE-086D-4CD0-BDE4-8B744915608EQ37211631-7F1BA5A6-7A52-4862-8556-559065FE942DQ37236103-EDEBB959-FCE6-4105-8AF2-A78D973698D8Q37543534-BDAA36E6-145B-4180-BCF1-C64E26E0A125Q38336321-20975D91-4BC5-4A67-902B-BB685F2A2C94Q39571686-23DD975D-5277-42E0-BEE6-CC598B5180CBQ54988307-C6AE5A35-DBDD-4741-B1D1-0690E38C6A96
P2860
Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Molecular imaging of prolifera ...... phy with [18F]fluorothymidine.
@en
Molecular imaging of prolifera ...... phy with [18F]fluorothymidine.
@nl
type
label
Molecular imaging of prolifera ...... phy with [18F]fluorothymidine.
@en
Molecular imaging of prolifera ...... phy with [18F]fluorothymidine.
@nl
prefLabel
Molecular imaging of prolifera ...... phy with [18F]fluorothymidine.
@en
Molecular imaging of prolifera ...... phy with [18F]fluorothymidine.
@nl
P2093
P50
P1433
P1476
Molecular imaging of prolifera ...... phy with [18F]fluorothymidine.
@en
P2093
Hans-Jürgen Wester
Ken Herrmann
Tobias Dechow
P304
P356
10.1016/J.YMETH.2009.03.009
P577
2009-03-24T00:00:00Z